

Academic – Research Team Athanasia Stamenitou Panagiota Giannakopoulou




Figure 1: Stock graph shows the bullish trend




Figure 2: BolBands present a strong buy position





Figure 3: MACD indicates a potential buy signal.





Firm's Brief Description

Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.

### **Fundamental Approach**

- Moderna's COVID-19 vaccine candidate met its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study
- Moderna announced supply agreement with United Kingdom Government to supply mRNA vaccine against COVID-19 (mRNA-1273) if approved for use
- European Medicines Agency begins rolling review of Moderna's mRNA vaccine candidate against COVID-19 (mRNA-1273)

### **Technical Analysis**

According to Figure 1, an overall upward trend was reported during the examined period (21/10/2020- 20/11/2020). MA10 crossed above MA20 providing a strong buy signal. Additionally, BolBands indicate a buy signal as well, as MRNA.O's stock crossed above the upper band, furthering its incline. From Figure 3, MACD crossed above its signal line pointing to a buy position. The Support and the Resistance levels were formed at 94.06 and 97.34 respectively. Last, a potential buy signal derives from CCI too, according to Figure 5.

### Prediction

Considering the technical analysis above and the positive momentum of the stock, a strong potential buy signal is recommended. This prediction is further supported by the evolutionary growth of the biotechnology sector in general due to the pandemic of Covid-19 and the strong bullish trend of the stock.



Moderna Inc., November 23 2020 MRNA.O, Biotechnology & Drugs Academic – Research Team Athanasia Stamenitou Panagiota Giannakopoulou

# DISCLAIMER

## THE FINANCE CLUB OF UNIVERSITY OF MACEDONIA, THESSALONIKI, GREECE

The Finance Club of University of Macedonia - www.financeclub.gr is an independent non-profitable student organization founded by students of the University of Macedonia, Greece (UoM - www.uom.gr) that aims to build strong relations between the market and the University. Though based in the University of Macedonia, it also operates via associates in Aristotle University of Thessaloniki, Greece and other institutions. The Club's goal is to give its members the chance to view the market in a more practical approach rather than solely relying on the abstract knowledge offered by the university. In order to achieve this goal, the Club organizes various events like conferences, workshops and seminars. Moreover, its members are able to cooperate with companies by taking up real case projects to work on along with the managers of the associated companies. In addition, the Club is trying to build and expand its network among students, market professionals and professors therefore giving its members a very broad pool of potential partners and employers.

This report has been compiled by the authors mentioned above and published by them via the Finance Club UoM site and many other platforms. The club confirms that the authors are active members at the time this article is published but emphasizes the fact that opinions and views given by the authors in this article are their own views. Finance Club UoM takes no responsibility for the completeness or correctness of information provided. No investment advice is given with the text above and the reader should not take any financial position based on the information published in this article. The Club recommends extensive research by the reader before investing in any financial asset. General this report may be based on the information extracted from various sources including but not limited to various companies' and statistical agencies' websites, online portals, third-party research, annual reports etc. No representation or warranty of any kind is or may be made with respect to the accuracy or completeness of, and no representation or warranty should be inferred from, any projections or futuristic statement contained herein or any underlying assumptions. This article may include descriptions, statements, estimates and projections/futuristic statements with respect to current and anticipated performance of the underlying. Such statements, estimates and projections reflect various assumptions and best estimates made by the participants concerning anticipated results, whose assumptions and estimates may or may not prove to be accurate or correct. There are no assurances whatsoever that any statements, estimates or projections contained in this article, including without limitation any financial or business projections, accurately present in all material respects the underlying's financial and/or business position as of the respective dates specified and the results of its operations for any respective periods indicated. No copyright or trademark infringement is intended in any form.

## © Copyright 2020. Finance Club UoM